Gilead Sciences (GILD): Rep. Carol D. Miller (WV01) disclosed a purchase $1K–$15K
Rep. Carol D. Miller (WV01) disclosed a purchase of Gilead Sciences in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 32 days
- Disclosure lag
- Traded
- Mar 10, 2025
- Disclosed
- Apr 11, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 15, 2025InsiderCFO sold ~$228K of GILD shares in the open market
- Jan 31, 2025InsiderCFO sold ~$13.8M of GILD shares in the open market
- Feb 12, 2025InsiderCFO sold ~$14.1M of GILD shares in the open market
- Feb 18, 2025InsiderCFO sold ~$260K of GILD shares in the open market
- Feb 19, 2025FDAFDA drug approval: Odefsey
- Feb 19, 2025FDAFDA drug approval: Odefsey
- Mar 7, 2025FDARecall: Sofosbuvir and Velpatasvir, 400 mg/100 mg tablets, 28 tablets: 2x14 blister cards, Rx Only, Manufactured for: Asegua Therapeutics LLC an affiliate of Gilead Sc…
- Mar 7, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
- Mar 10, 2025 · this disclosureCongressDisclosed purchase of GILD — reported range $1,001 - $15,000
What came next
- Mar 10, 2025Insider · 1 personInsiders: 2 sales (~$2.1M)
- Mar 17, 2025InsiderCFO sold ~$276K of GILD shares in the open market
- Mar 31, 2025CongressDisclosed purchase of GILD — reported range $15,001 - $50,000
- Apr 15, 2025InsiderCFO sold ~$266K of GILD shares in the open market
- Apr 16, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
- May 5, 2025Congress · 1 personMembers of Congress: 3 purchases
- May 12, 2025CongressDisclosed sale of GILD — reported range $15,001 - $50,000
- May 14, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
- May 15, 2025InsiderCFO sold ~$250K of GILD shares in the open market
- May 22, 2025Insider · 1 personInsiders: 3 sales (~$3.0M)
- May 30, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
- Jun 6, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
- Jun 16, 2025Insider · 2 peopleInsiders: 2 sales (~$606K)
- Jun 18, 2025FDAFDA drug approval: Yeztugo
- Jun 18, 2025FDAFDA drug approval: Yeztugo
- Jun 20, 2025FDAFDA drug approval: Tybost
- Jun 20, 2025FDAFDA drug approval: Tybost
- Jun 20, 2025FDAFDA drug approval: Descovy
- Jun 20, 2025FDAFDA drug approval: Descovy
- Jun 30, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Gilead Sciences
For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.
Other recent filings by Rep. Carol D. Miller (WV01)
- House Clerk periodic transaction report at Pfizer (PFE)Aug 13, 2026
- House Clerk periodic transaction report at Quest Diagnostics (DGX)Aug 13, 2026
- House Clerk periodic transaction report at Target (TGT)Aug 13, 2026
- House Clerk periodic transaction report at U.S. Bancorp (USB)Aug 13, 2026
- House Clerk periodic transaction report at U.S. Bancorp (USB)Apr 11, 2025
The full history of Rep. Carol D. Miller (WV01) is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded Gilead Sciences (GILD) stock, and how much?
Rep. Carol D. Miller (WV01) disclosed a purchase of Gilead Sciences in the $1K–$15K range. Reported range, not an exact amount.
When did it happen, and when was it made public?
Traded: Mar 10, 2025. Disclosed: Apr 11, 2025. That is 32 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Gilead Sciences recently?
For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.
Does this mean GILD stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Gilead Sciences
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 16, 2026
Everything OQRO holds on this company is on its GILD page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
